Therapeutic efficacy of benzoxazinorifamycin KRM-1648 against experimental murine tuberculosis: (1) A study on the efficacy of short course treatment with the intratracheal and intravenous infection models

Kekkaku

Volumn 73, Issue 2, 1998, Pages 53-64

  Doi, Norio ^a  

^a RESEARCH INSTITUTE OF TUBERCULOSIS   (Japan)

Author keywords

Intratracheal infection; KRM 1648; Mouse; Mycobacterium tuberculosis; Rifabutin; Rifampicin

Indexed keywords

RIFABUTIN; RIFALAZIL; RIFAMPICIN; RIFAMYCIN DERIVATIVE; TUBERCULOSTATIC AGENT;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; EXPERIMENTAL INFECTION; INTRATRACHEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; MYCOBACTERIOSIS; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; SURVIVAL RATE; TREATMENT OUTCOME; TUBERCULOSIS;

ANIMALS; ANTIBIOTICS, ANTITUBERCULAR; FEMALE; MICE; MICE, INBRED BALB C; MYCOBACTERIUM BOVIS; RIFABUTIN; RIFAMPIN; RIFAMYCINS; TUBERCULOSIS;

EID: 0031943918     PISSN: 00229776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Yamane T, Hashizume T, Yamashita K, et al. : Synthesis and biological activity of 3'-hydroxy-5′-aminobenzoxazinorifamycin derivatives. Chem Pharm Bull. 1993 ; 41 : 148-155.
2. Hosoe K, Konishi E, Hidaka T, et al. : High-performance liquid Chromatographie determination of 3′-hydroxy-5′-(4-isobutyl-1-piperazinyl) benzoxazinorifamycin (KRM-1648) and its deacetyl metabolite in plasma, whole blood, urine and tissue samples in rats. J Chromatogr B. 1994 ; 653 : 177-186.
3. Hosoe K, Mae T, Konishi E, et al. : Pharmacokinetics of KRM-1648, a new benzoxazinorifamycin, in rats and dogs. Antimicrob Agents Chemother. 1996 ; 40 : 2749-2755.
4. Mycobacterium tuberculosis M. avium complex in vitro 1990; 65 : 31-36.
5. Rifamycm Mycobacterium tuberculosis M. avium complex in vivo 1991 ; 66: 7-12.
6. Saito H, Tomioka H, Sato K, et al. : In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins. Antimicrob Agents Chemother. 1991 ; 35 : 542-547.
7. Tomioka H, Saito H, Sato K, et al. : Chemotherapeutic efficacy of a newly synthesized benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex infection induced in mice. Antimicrob Agents Chemother. 1992 ; 36 : 387-393.
8. Tomioka H, Saito H, Fujii K, et al. : In vitro antimicrobial activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex, determined by the radiometric method. Antimicrob Agents Chemother. 1993 ; 37 : 67-70.
9. Emori M, Saito H, Sato K, et al. : Therapeutic efficacy of the benzoxazinorifamycin KRM-1648 against experimental Mycobacterium avium infection induced in rabbits. Antimicrob Agents Chemother. 1993 ; 37 : 722-728.
10. Inderlied CB, Barbara-Burnham L, Wu M, et al. : Activities of the benzoxazinorifamycin KRM-1648 and ethambutol against Mycobacterium avium complex in vitro and in macrophages. Antimicrob Agents Chemother. 1994 ; 38 : 1838-1843.
11. Bermudez LE, Kolonoski P, Young LS, et al. : Activity of KRM-1648 alone or in combination with ethambutol or clarithromycin against Mycobacterium avium in beige mouse model of disseminated infection. Antimicrob Agents Chemother. 1994; 38:1844-1848.
12. Klemens SP, Grossi MA, Cynamon MH : Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model. Antimicrob Agents Chemother. 1994 ; 38 : 2245-2248.
13. Saito H, Tomioka H, Sato K, et al. : Therapeutic effect of KRM-1648 with various antimicrobials against Mycobacterium avium complex infection in mice. Tubercle and Lung Dis. 1995 ; 76 : 51-58.
14. Luna-Herrera J, Reddy MV, Gangadharam PRJ, et al. : In vitro activity of the benzoxazinorifamycin KRM-1648 against drug-susceptible and multidrug-resistant tubercle bacilli. Antimicrob Agents Chemother. 1995 ; 39 : 440-444.
15. Hirata T, Saito H, Tomioka H, et al. : In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1995 ; 39 : 2295-2303.
16. Klemens SP, Cynamon MH : Activity of KRM-1648 in combination with isoniazid against Mycobacterium tuberculosis in a murine model. Antimicrob Agents Chemother. 1996 ; 40 : 298-301.
17. Yamamoto T, Amitani R. Suzuki K, et al. : In vitro bactericidal and in vivo therapeutic activities of a new rifamycin derivative, KRM-1648, against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1996 ; 40 : 426-428.
18. Yamamoto T, Amitani R, Suzuki K, et al. : Activity of KRM - 1648 alone or in combination with both ethambutol and kanamycin or clarithromycin against Mycobacterium intracellulare infections in beige mice. Antimicrob Agents Chemother. 1996 ; 40 : 429-432.
19. Baohong JI, Lounis N, Truffot-Pernot C, et al. : How effective is KRM-1648 in treatment of disseminated Mycobacterium avium complex infections in beige mice. Antimicrob Agents Chemother. 1996 ; 40 : 437-442.
20. Mor N, Simon B, Heifets L : Bacteriostatic and bactericidal activities of benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium in human macrophages. Antimicrob Agents Chemother. 1996 ; 40 : 1482-1485.
21. Youmans GP : Subsurface growth of virulent human tubercle bacilli in a synthetic medium. Proc Soc Exp Biol Med. 1944 ; 57 : 122-125.
22. Green CG, Knight J, Precious S, et al. : Ketamine alone and combined with diazepam or xylazine in laboratory animals : a 10 year experience. Laboratory Animals. 1981 ; 15: 163-170.
23. Brogden RN, Fitton A : Rifabutin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1994 ; 47 : 983-1009.
24. Orme IM : Antimycobacterial activity in vivo of LM427 (rifabutin). Am Rev Respir Dis. 1988 ; 138: 1254-1257.
25. Klemens SP, Grossi MA, Cynamon MH : Comparative in vivo activities of rifabutin and rifapentine against Mycobacterium avium complex. Antimicrob Agents Chemother. 1994 ; 38: 234-237.
26. Heifets LB, Lindholm-Levy PJ, Flory MA : Bactericidal activity in vitro of various rifamycmins against Mycobacterium avium and Mycobacterium tuberculosis. Am Rev Respir Dis. 1990 ; 141 : 626-630.
27. Saito H, Sato K, Tomioka H : Comparative in vitro and in vivo activity of rifabutin and rifampicin against Mycobacterium avium complex. Tubercle. 1988 ; 69 : 187-192.
28. Dhillon J, Dickinson JM, Guy JA, et al. : Activity of two long-acting rifamycins, rifapentine and FCE 22807, in experimental murine tuberculosis. Tubercle and Lung Dis. 1992 ; 73 : 116-123.
29. Rifampicin (RFP) 1970:23:961-968.
30. Dickinson JM, Mitchison DA : Suitability of rifampicin for intermittent administration in the treatment of tuberculosis. Tubercle. 1970 ; 51 : 82-94.
31. Nightingale SD, Cameron DW, Gordin FM, et al. : Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med. 1993 ; 329: 828-833.
32. Gonzalez-Montaner LJ, Natal S, Yongchaiyud P, et al. : Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis : a multinational, randomized, comparative study versus rifampicin. Tubercle and Lung Dis. 1994 ; 75 : 341-347.
33. Schwander S, Rüsch-Gerdes S, Mateega A, et al. : A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. Tubercle and Lung Dis. 1995 ; 76 : 210-218.
34. Havlir DV, Dube MP, Sattler FR, et al. : Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. N Engl J Med. 1996 ; 335 : 392-398.
35. Dautzenberg B, Castellani P, Pellegrin JL : Early bactericidal activity of rifabutin versus that of placebo in treatment of disseminated Mycobacterium avium complex bacteremia in AIDS patients. Antimicrob Agents Chemother. 1996 ; 40 : 1722-1725.
36. Kelly BP, Furney SK, Jessen MT, et al. : Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1996 ; 40 : 2809-2812.
37. MacCune RM, Tompsett R : The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique II . J Exp Med. 1956 ; 104 : 763-802.
38. Dhillon J, Dickinson JM, Sole K, et al. : Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide. Antimicrob Agents Chemother. 1996 ; 40 : 552-555.
39. Dunn PL, North RJ : Virulence ranking of some Mycobacterium tuberculosis and Mycobacterium bovis strains according to their ability to multiply in the lungs, induce lung pathology, and cause mortality in mice. Infect Immun. 1995 ; 63 : 3428-3437.
40. Steenken W, Gardner LU : History of H37 strain of tubercle bacillus. Am Rev Tuber. 1946 ; 54 : 62-66.
41. Kradolfer F, Schnell R : Incidence of resistant pulmonary tuberculosis in relation to initial bacterial load. Rifampicin and INH in experimental tuberculosis. Chemotherapy. 1970 ; 15 : 242-249.
42. Doi N, Aoki M : Benzoxazinorifamycin KRM-1648, therapeutic efficacy against experimental murine tuberculosis. Tubercle Lung Dis. Suppl 1. 1994 ; 75 : 35.